NCT03521973View on ClinicalTrials.gov

Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

May 18, 2021

Study Completion Date

August 3, 2021

Conditions
Malaria
Interventions
BIOLOGICAL

PfSPZ Vaccine

Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)

OTHER

Normal Saline

0.9% Sodium chloride

Trial Locations (1)

Unknown

Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné

All Listed Sponsors
collaborator

Centre de Recherches Médicales de Lambaréné (CERMEL), German Center for Infection Research

UNKNOWN

lead

Sanaria Inc.

INDUSTRY

NCT03521973 - Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children | Biotech Hunter | Biotech Hunter